The drugmaker from the US said it tested three different doses of LY-CoV555, which was against a placebo in a trial that recruited about 450 patients. A median dose of 2,800 mg met the test goal to reduce the presence of SARS-CoV-2 after 11 days.
Other doses of antibody-drug, including a dose of 700 mg and a dose of 7,000 mg, did not meet that goal.
The announcement comes at a time when many are closely monitoring the development of antibody drugs as a potential bridge to the coronary vaccine.
To date, more than 29.5 million people have contracted Kovid-19 worldwide with 935,591 related deaths, according to data compiled by Johns Hopkins University.
“These interim data from the BLAZE-1 trial suggest that LY-CoV555, an antibody specifically directed against SARS-CoV-2, has direct antiviral effects and may reduce COVID-related hospitals.” Daniel Skowronski, Chief Scientific Officer and President of Lilly. Lily said in a statement by research laboratories.
“The results reinforce our belief that neutralizing antibodies can help in the fight against COVID-19,” Skowrowski said.
Eli Lilly shares rose 2.6% in pre-market trade soon after the announcement.
LY-CoV555 belongs to a class of therapies known as monoclonal antibodies. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus and potentially preventing and treating coronaviruses.
Antibodies developed by Eli Lilly and Abler were identified from a blood sample taken from one of the first American patients to be recovered from Kovid-19.
Eli Lilly is one of several companies developing GlaxoSmithKline and Regeneron Pharmaceuticals as well as antibody drugs.